Aureobasidium.org

Review 2018

Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles

Zhang, Mei; Kim, Julian A.; Huang, Alex Yee-Chen · Frontiers in Immunology · DOI: 10.3389/fimmu.2018.00341
Research Archive
TL;DR — Key Findings
  • Review of beta-glucan strategies for changing the tumor microenvironment.
  • Mechanistic and preclinical evidence suggests possible immune-modulating effects.
  • No human efficacy conclusion or direct Aureobasidium product evidence.

Abstract

This review examines beta-glucans and beta-glucan-based nanoparticles as possible tools for modifying the immunosuppressive tumor microenvironment. It discusses recognition by innate immune receptors, effects on antigen-presenting cells and myeloid cells, and delivery strategies intended to support anti-tumor immune responses. The article brings together mechanistic and mainly preclinical evidence; it does not establish clinical efficacy in people or specifically test Aureobasidium pullulans beta-glucan.

Summary

Summary

What was studied

A review of beta-glucans and beta-glucan nanoparticles as immune modulators of the tumor microenvironment.

What the evidence suggests

Receptor-mediated effects on myeloid and antigen-presenting cells may help make some tumors more responsive to immune attack.

How to interpret it

The evidence is mainly mechanistic and preclinical. This is not a human efficacy trial and not a direct test of Aureobasidium pullulans beta-glucan.

AI-generated summary for accessibility. Always refer to the original paper.

Citation

Zhang, Mei; Kim, Julian A.; Huang, Alex Yee-Chen. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles. Frontiers in Immunology. 2018. DOI: 10.3389/fimmu.2018.00341.

Study Details
Study Type
Review
Published
2018
Journal
Frontiers in Immunology
Authors
Zhang, Mei; Kim, Julian A.; Huang, Alex Yee-Chen
Important Notice

For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.